Carvolix

Historical price data

Carvolix, founded by Truffle Capital in 2026, is a unified entity created from the merger of Caranx Medical, Artedrone, and Affluent Medical, with the mission to expand patient access to complex valve and stroke procedures. The company has achieved key milestones, including FDA clearance and first-in-human use of its TAVIPILOT AI software and robotic system for transcatheter aortic valve implantation (TAVI). Its strategy leverages a synergistic platform of AI, robotics, and next-generation implants to empower the large, underutilized base of interventional cardiologists, aiming to transform the catheterization lab into an efficient, 'autopilot'-enabled environment.

An integrated platform combining AI-driven software for real-time intra-operative guidance, mini-robotic hardware for precise device manipulation, and next-generation biomimetic implants, all designed to provide 'supervised autonomy' for complex cardiac and neurovascular procedures.

Carvolix faces indirect competition from broad surgical robotics players (Intuitive Surgical) and imaging/guidance giants (Siemens, Philips), but its vertically integrated, procedure-specific platform combining AI, mini-robotics, and implants is currently unique. Its most direct competitor is Corindus (Siemens) for vascular robotics, but Carvolix's focus on TAVI and stroke provides a specialized edge.